Skip to content

Erasca, Inc. ERAS Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$46.37B+0.8%
Eli Lilly logo
Eli LillyLLY
$6.92B+0.2%
Pfizer logo
PfizerPFE
$94.77B+1.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$4.82B+19.8%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.04B+46.9%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.77B+3.2%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s additional paid-in capital?
Erasca, Inc. (ERAS) reported additional paid-in capital of $1.47B in Q1 2026.
How has Erasca, Inc.'s additional paid-in capital changed year-over-year?
Erasca, Inc.'s additional paid-in capital increased by 22.7% year-over-year, from $1.2B to $1.47B.
What is the long-term trend for Erasca, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Erasca, Inc.'s additional paid-in capital has grown at a 286.4% compound annual growth rate (CAGR), from $1.41M to $1.22B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.